

• **Name:** Yoon-La Choi

• **Current Position:** Professor

• **Country:** Republic of Korea

• **Educational Background:**

1996. 2. M.D. Seoul National University College of Medicine, Seoul, Korea

2002. 2. Ph.D. Seoul National University College of Medicine, Seoul, Korea

• **Professional Experience:**

2002. 3-2003.7 : Research fellow, Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

2006.3-2007.12 : Clinical Visiting instructor, Department of Pathology, Stanford University, Palo Alto, U.S.A

2008.3-2012.2 : Assistant Professor, Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Korea

2012.3-2018.2 : Associate Professor, Department of Pathology, Samsung Medical Center,

Sungkyunkwan University, Korea

2018.3-present : Professor, Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Korea

• **Professional Organizations:**

- Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea

• **Main Scientific Publications:**

1. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. *Int J Mol Sci.* 2019 Sep 26;20(19). pii: E4794. doi: 10.3390/ijms20194794.

2. Molecular changes in solitary fibrous tumor progression. *J Mol Med (Berl).* 2019 Oct;97(10):1413-1425. doi: 10.1007/s00109-019-01815-8. Epub 2019 Jul 18.

3. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. *Lab Invest.* 2019 Sep;99(9):1309-1320. doi: 10.1038/s41374-019-0263-4. Epub 2019 Jun 3.
4. Status of programmed death-ligand 1 expression in sarcomas. *J Transl Med.* 2018 Nov 6;16(1):303. doi: 10.1186/s12967-018-1658-5.
5. Integrin β 3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC. *Clin Cancer Res.* 2018 Sep 1;24(17):4162-4174. doi: 10.1158/1078-0432.CCR-17-3492. Epub 2018 May 18.
6. Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. *Oncotarget.* 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.
7. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. *J Thorac Oncol.* 2017 May 10.
8. Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients. *Cancer Res Treat.* 2017 Jan 25.
9. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. *Oncotarget.* 2016 Oct 14.
10. Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma. *J Thorac Oncol.* 2016 Sep 9